Press Releases

May 2026

LTZ Therapeutics Raises $38 Million in Support of Advancing Myeloid Engager Immunotherapy Pipeline

REDWOOD CITY, California and SHENZHEN, China – May 6, 2026 – LTZ Therapeutics, a clinical-stage, immunotherapy-focused biotechnology company, today announced the completion of an oversubscribed $38 million financing round to accelerate development of its Universal Myeloid Cell Engager (U-MCETM)-based immunotherapy pipeline, particularly its lead asset LTZ-301 targeting oncology and autoimmune diseases.
November 2025

GSK and LTZ announce strategic collaboration to advance novel myeloid cell engagers in oncology
July 2025

LTZ Therapeutics Announces Strategic Collaboration with Eli Lilly to Advance Development of its Myeloid Engager Platform for Autoimmune Diseases
February 2025

LTZ Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of First-in-Class Myeloid Engager Immunotherapy, LTZ-301
July 2024

LTZ Therapeutics Announces Over $20 Million Series A Financing for Development of its Myeloid Engager-Based Immunotherapy Pipeline
May 2023

LTZ Announces over $10 Million Pre-A+ Financing to Advance Development of its Immunotherapy Pipeline to Treat Cancer and Autoimmune Diseases
April 2022

LTZ Therapeutics Secures $17 Million Pre-Series A Financing for Immunotherapy Development to Treat Cancer & Other Complex Diseases

In The News

Follow Us
  • Stay ln Touch

    General Inquiries

    info@ltztherapeutics.com

    Business Development

    vivian.tian@ltztherapeutics.com
  • Locations

    Redwood City, USA

    1100 Island Dr., Suite 103, Redwood City, CA, 94065

    Shenzhen, China

    Room 3004, Building B, New Building of Research Institute of Tsinghua University in Shenzhen, Yuehai Sub-district, High-tech Zone Community, Gaoxin South 39th Road, Nanshan District, Shenzhen 518057

@ 2026 LTZ Therapeutics Inc., All Rights Reserved.

Privacy Policy | Term of Use | Contact Us

为了更好的呈现效果，移动端请竖屏浏览